These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 16721314)

  • 1. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder.
    Pliszka SR; Crismon ML; Hughes CW; Corners CK; Emslie GJ; Jensen PS; McCRACKEN JT; Swanson JM; Lopez M;
    J Am Acad Child Adolesc Psychiatry; 2006 Jun; 45(6):642-657. PubMed ID: 16721314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part I. Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR; Greenhill LL; Crismon ML; Sedillo A; Carlson C; Conners CK; McCracken JT; Swanson JM; Hughes CW; Llana ME; Lopez M; Toprac MG
    J Am Acad Child Adolesc Psychiatry; 2000 Jul; 39(7):908-19. PubMed ID: 10892234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part II: Tactics. Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR; Greenhill LL; Crismon ML; Sedillo A; Carlson C; Conners CK; McCracken JT; Swanson JM; Hughes CW; Llana ME; Lopez M; Toprac MG
    J Am Acad Child Adolesc Psychiatry; 2000 Jul; 39(7):920-7. PubMed ID: 10892235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) and comorbid disorders].
    Wiesegger G; Kienbacher C; Pellegrini E; Scheidinger H; Vesely C; Bangerl W; Friedrich M
    Neuropsychiatr; 2007; 21(3):187-206. PubMed ID: 17915180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.
    Cottrell S; Tilden D; Robinson P; Bae J; Arellano J; Edgell E; Aristides M; Boye KS
    Value Health; 2008; 11(3):376-88. PubMed ID: 18489664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK.
    Prasad S; Arellano J; Steer C; Libretto SE
    Int J Clin Pract; 2009 Jul; 63(7):1031-40. PubMed ID: 19570121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment receipt and outcomes from a clinic employing the attention-deficit/hyperactivity disorder treatment guideline of the children's medication algorithm project.
    Wagner DJ; Vallerand IA; McLennan JD
    J Child Adolesc Psychopharmacol; 2014 Nov; 24(9):472-80. PubMed ID: 25329880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder.
    Geller D; Donnelly C; Lopez F; Rubin R; Newcorn J; Sutton V; Bakken R; Paczkowski M; Kelsey D; Sumner C
    J Am Acad Child Adolesc Psychiatry; 2007 Sep; 46(9):1119-1127. PubMed ID: 17712235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data.
    Biederman J; Spencer TJ; Newcorn JH; Gao H; Milton DR; Feldman PD; Witte MM
    Psychopharmacology (Berl); 2007 Jan; 190(1):31-41. PubMed ID: 17093981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.
    Holzer B; Lopes V; Lehman R
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):415-8. PubMed ID: 23952189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder.
    Hazell P; Zhang S; Wolańczyk T; Barton J; Johnson M; Zuddas A; Danckaerts M; Ladikos A; Benn D; Yoran-Hegesh R; Zeiner P; Michelson D
    Eur Child Adolesc Psychiatry; 2006 Mar; 15(2):105-10. PubMed ID: 16523251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder.
    Chang K; Nayar D; Howe M; Rana M
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):547-51. PubMed ID: 19877979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents.
    Scott NG; Ripperger-Suhler J; Rajab MH; Kjar D
    J Child Adolesc Psychopharmacol; 2010 Jun; 20(3):197-203. PubMed ID: 20578932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
    De Bruyckere K; Bushe C; Bartel C; Berggren L; Kan CC; Dittmann RW
    CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder.
    Crismon ML; Trivedi M; Pigott TA; Rush AJ; Hirschfeld RM; Kahn DA; DeBattista C; Nelson JC; Nierenberg AA; Sackeim HA; Thase ME
    J Clin Psychiatry; 1999 Mar; 60(3):142-56. PubMed ID: 10192589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating common psychiatric disorders associated with attention-deficit/hyperactivity disorder.
    Kunwar A; Dewan M; Faraone SV
    Expert Opin Pharmacother; 2007 Apr; 8(5):555-62. PubMed ID: 17376012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
    Kelsey DK; Sumner CR; Casat CD; Coury DL; Quintana H; Saylor KE; Sutton VK; Gonzales J; Malcolm SK; Schuh KJ; Allen AJ
    Pediatrics; 2004 Jul; 114(1):e1-8. PubMed ID: 15231966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M; Munda B; Svab V; Locatelli I
    J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.